1. Beri, Nina. 2022. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. In Future oncology (London, England), 18, 1391-1402. doi:10.2217/fon-2021-1089. https://pubmed.ncbi.nlm.nih.gov/35081733/
2. Goyal, Lipika, Shi, Lei, Liu, Leah Y, Corcoran, Ryan B, Bardeesy, Nabeel. 2019. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. In Cancer discovery, 9, 1064-1079. doi:10.1158/2159-8290.CD-19-0182. https://pubmed.ncbi.nlm.nih.gov/31109923/
3. Jahan, Nusrat, Begum, Mobashera, Barek, Md Abdul, Abdulabbas, Hadi Sajid, Islam, Mohammad Safiqul. 2023. Evaluation of the Association between FGFR2 Gene Polymorphisms and Breast Cancer Risk in the Bangladeshi Population. In Genes, 14, . doi:10.3390/genes14040819. https://pubmed.ncbi.nlm.nih.gov/37107577/
4. Haworth, Kim E, Farrell, William E, Emes, Richard D, Mein, Charles, Fryer, Anthony A. . Methylation of the FGFR2 gene is associated with high birth weight centile in humans. In Epigenomics, 6, 477-91. doi:10.2217/epi.14.40. https://pubmed.ncbi.nlm.nih.gov/25431941/